Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
20 sept. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
13 sept. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE...
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
09 sept. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open
07 sept. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
02 sept. 2021 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
02 sept. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
09 août 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021Positive feedback from FDA clarifies potential path forward in ASDCash runway...
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
04 août 2021 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
07 juil. 2021 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
30 juin 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
- 49% of shares voted, quorum not established to hold annual meeting – - Meeting scheduled to reconvene August 3, 2021 at 9:00 AM EDT – - Company strongly encourages stockholders holding unvoted...